Scribd
Upload
19 views

Ferritin 1

The document discusses several studies related to clinical vascular disease. It includes summaries of studies that examined the relationship between initial serum ferritin levels and in-hospital mortality in STEMI patients, the efficacy and safety of saroglitazar compared to fenofibrate in patients with hypertriglyceridemia, and the clinical impact of circulating miR-21-5p levels on the severity of coronary artery disease.

Uploaded by

Surya
Copyright
© © All Rights Reserved
Available Formats
Download as PDF, TXT or read online on Scribd
19 views

Ferritin 1

The document discusses several studies related to clinical vascular disease. It includes summaries of studies that examined the relationship between initial serum ferritin levels and in-hospital mortality in STEMI patients, the efficacy and safety of saroglitazar compared to fenofibrate in patients with hypertriglyceridemia, and the clinical impact of circulating miR-21-5p levels on the severity of coronary artery disease.

Uploaded by

Surya
Copyright
© © All Rights Reserved
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

Abstracts / 355 (2022) e83ee351 e339

Methods: 77 SH adults from the Da Vinci FH Detection Study in Argentina Angiology Unit, Clinical And Experimental Internal Medicine Department,
were included: 34 on statins (30/34 on atorvastatin -10/20 mg- and Medical Research Institute Alexandria University, Alexandria, Egypt;
3
rosuvastatin 10 mg), 13 on S+E and 30 without LLT. All patients were Cardiology Department, Faculty of Medicine Alexandria University,
genetically tested, 36/77 cases had pathogenic variants in FH genes and 8/ Alexandria, Egypt; 4 Cardiology Department, Houston Methodist DeBakey
77 showed high LDL polygenic risk score, which explains their phenotype. Heart & Vascular Center, Houston, United States of America
Added to the lipid profile, serum PCSK9 was measured by ELISA
Results: PCSK9 showed an increase through the 3 groups (mean±SD ng/ Background and Aims : In addition to iron homeostasis, an iron-storage
mL) no LLT: 242±107, statins: 323±129 and S+E: 392±100, p<0.001. One- protein, ferritin, plays a role in various pathological conditions including
way ANOVA contrast analysis showed differences among groups: no inflammatory and malignant diseases. Several studies showed that
treatment vs statins p<0.001, vs statin+ezetimibe p<0.001 and differences elevated serum ferritin level was associated with a higher risk of coronary
between statins vs S+E showed a trend that did not reach significance artery disease. Recently, it has been shown that high serum ferritin levels
(p¼0.07), probably due to low number of patients in S+E group. PCSK9 in men independently correlated with an increased risk of cardiovascular
maintained significant correlation with apoB r¼0.27; p<0.02. mortality. The study aimed to investigate the possible correlation between
Conclusions: Given that primary LLT (S+E) increase PCSK9 levels, phar- the initial serum ferritin level and the in-hospital mortality in patients
macologic strategies against PCSK9 might be one of the most effective presented by ST-elevation myocardial infarction (STEMI).
approaches to achieving very low LDL-C neutralizing the concomitant
increase of PCSK9 Methods: A total number of 890 patients presented by acute STEMI from
the period from 1/5/2020 to 1/5/2021 and underwent successful primary
percutaneous coronary intervention (PPCI) according to the standard
EP745 / #290, TOPIC: ASA04 - CLINICAL VASCULAR DISEASE / ASA04-13 techniques. Initial serum ferritin level was measured in all patients at the
NEW LIPID LOWERING THERAPIES, POSTER VIEWING SESSION. time of admission. Patients with a history of anemia or on iron supple-
EFFICACY AND SAFETY OF SAROGLITAZAR 4 MG COMPARED TO mental therapy were excluded from the study.
FENOFIBRATE 160 MG IN LATINO ADULTS WITH MODERATE TO Results: 41 patients had in-hospital mortality while 849 patients survived.
SEVERE HYPERTRIGLYCERIDEMIA-A RANDOMIZED CLINICAL TRIAL There was no significant difference between both groups regarding base-
line clinical characteristics. By comparing initial serum ferritin levels in the
D. Parmar 1, R. Rodriguez-Gutierrez 2, J.G. Gonza lez-Gonz
alez 3, F. 2 groups, it was higher in deceased patients (p-value¼ 0.0004*).
 pez 5. 1 Clinical Research And Development, Zydus
Shaikh 4, J.L.P. Cruz-Lo
Therapeutics Inc., Pennington, United States of America; 2 Endocrinology,
UANL, Monterrey, M exico and Mayo Clinic, Rochester, MN, USA, Monterrey,
Mexico; 3 Endocrinology, UANL, Monterrey, M exico. Facultad de Medicina y
Hospital Universitario "Dr. Jos e Eleuterio Gonza lez", Monterrey, Mexico;
4
Clinical Research And Development, Zydus Worldwide DMCC, Dubai,
United Arab Emirates; 5 Clinical Development, Avant Sante Research Center
SA de CV., Monterrey, Mexico

Background and Aims : To assess the efficacy and safety of saroglitazar 4


mg in patients with moderate to severe hypertriglyceridemia in compar-
ison with fenofibrate 160 mg.

Methods: This was a multicenter, randomized, double-blinded, double-


dummy, active-control non-inferiority trial in patients aged above 18 years
with fasting triglycerides level of 500 mg/dL to 1500 mg/dL. Patients were
randomized in a 1:1 ratio to receive daily dose of saroglitazar 4 mg or ĂConclusions: There was a positive correlation between initial serum
fenofibrate 160 mg for 12 weeks. The primary efficacy endpoint was the ferritin level and in-hospital mortality in acute STEMI patients. Further
percent change in triglyceride (TG) levels at Week 12 relative to baseline. studies are required to determine the prognostic impact of ferritin levels in
The primary analysis was conducted based on the per-protocol population patients with stable coronary artery disease and acute coronary syn-
(PP) using a non-inferiority margin of 4%. dromes.
Results: The PP population consisted of 41 patients in the saroglitazar
group and 41 patients in the fenofibrate group. The percent reduction from
baseline in TG levels at Week 12 was higher in favor of saroglitazar group EP747 / #1348, TOPIC: ASA04 - CLINICAL VASCULAR DISEASE / ASA04-14
(LS Mean -55.3%, SE ¼ 4.9) compared with fenofibrate group (LS Mean ¼ OTHER, POSTER VIEWING SESSION.
-41.1%, SE ¼ 4.9). The LS estimate of the mean difference in percent change CLINICAL IMPACT OF CIRCULATING MICRORNA-21-5P ON THE SEVERITY
in TG levels at Week 12 was 14.1%, with the lower limit of the two-sided OF CORONARY ARTERY DISEASE
95% confidence interval being 0.14% which is greater than the non-inferi-
ority margin. Overall, 37 treatment-emergent adverse events (AE) were M.S. Ali Sheikh. College Of Medicine, Internal Medicine Department, Jouf
reported in 24 patients (Saroglitazar: 13, Fenofibrate: 11). No serious AEs University, Sakaka, Saudi Arabia
were reported and no patient discontinued the study due to AEs.
Conclusions: This trial showed saroglitazar 4 mg is non-inferior to feno- Background and Aims : To explore the clinical value of circulatory miR-
fibrate 160 mg in reducing TG levels at Week 12. Saroglitazar was safe and 21-5p as an early non-invasive biomarker for coronary artery disease
well-tolerated. (CAD) patients and the degree of coronary artery stenosis.

Methods: Invasive angiographically confirmed 87 multivessel lesion CAD,


EP746 / #744, TOPIC: ASA04 - CLINICAL VASCULAR DISEASE / ASA04-14 73 double vessel lesion CAD, 35 single vessel CAD patients and 35 healthy
OTHER, POSTER VIEWING SESSION. subjects were enrolled in this study.
INITIAL SERUM FERRITIN LEVEL AS A PREDICTOR OF IN-HOSPITAL Results: Circulatory plasma miR-21-5p expressions were gradually and
MORTALITY IN PATIENTS PRESENTED BY ST-ELEVATION MYOCARDIAL significantly elevated in single, double, and multi-vessel occluded CAD
INFARCTION subjects as compared with healthy participants (p<0.001). Muti-vessel
CAD (AUC: 0.962), double vessel CAD (AUC: 0.953) and single vessel CAD
M. Abdelnabi 1, 2, A. Almaghraby 3, J. Benjanuwattra 1, Y. Saleh 4, A. Mokhtar (AUC:0.947) patients were able to significantly differentiated from healthy
Abd El Azeem 3. 1 Internal Medicine Department, Texas Tech University subjects with remarkable specificity and sensitivity. Plasma miR-21-5p
Health Science Center, Lubbock, United States of America; 2 Cardiology And concentrations in single, double and multi-vessel geriatric (65-85 years)

You might also like